Clinical Trial Update: Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating interleukin-21 for metastatic or recurrent malignant melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Interleukin-21 (Interleukin-21)

Snippet

Sponsor: NCIC Clinical Trials Group | Conditions: Melanoma (Skin) | Phase 2 | Status: COMPLETED